China approves Pfizer GLP-1 drug for weight loss

2026-03-10 06:55:07

Abstract generation in progress

China has approved Pfizer’s GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, boosting competition in a market expected to be worth billions. Pfizer licensed the China commercialization rights for ecnoglutide from Sciwind Biosciences, which called the approval a breakthrough. This move solidifies Pfizer’s position in the expanding weight-loss drug market, which already features significant sales from competitors like Novo Nordisk and Innovent Biologics.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes